VBIV on NASDAQ
Cambridge, Massachusetts headquartered biopharmaceutical company
Prior to its bankruptcy proceedings in 2024, VBI Vaccines faced significant operational, financial, and organizational challenges, which many former employees attributed to poor leadership and ineffective management decisions. Critics of the company pointed to inconsistent strategic direction, questionable resource allocation, and repeated restructuring efforts that negatively affected morale and long-term stability.2 Its shares trade on NASDAQ under the symbol VBIV.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 20, 2026.
See how the biggest companies compare on our leaderboards
Prior to its bankruptcy proceedings in 2024, VBI Vaccines faced significant operational, financial, and organizational challenges, which many former employees attributed to poor leadership and ineffective management decisions. Critics of the company pointed to inconsistent strategic direction, questionable resource allocation, and repeated restructuring efforts that negatively affected morale and long-term stability. Some former staff members argued that scientific innovation, employee development, and retention were not adequately prioritized despite the company’s strong scientific potential. Management including CEO, CFO, CSO, and senior team was also criticized for being disconnected from employees’ concerns and for fostering a culture in which staff felt undervalued and unsupported during periods of financial difficulty and organizational change.2
VBI Vaccines sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
By 2007, VBI had received financial support from the National Research Council of Canada's Industrial Research Assistance Program, Innovation, Science and Economic Development Canada and Investissement Quebec. The company was originally financed by Clarus Ventures, a global life sciences venture capital firm under then CEO is Jeffrey Leiden, ARCH Venture Partners, 5AM Ventures and other private investors.
From Wikipedia’s article on VBI Vaccines, shared under CC BY-SA 4.0.3
From Wikidata.1
The numbers on this page point here. Each one links to the record it came from.